The Swedish Life Sciences Trend Analysis 2015

About Us

The following statistical information has been obtained from Biotechgate. Biotechgate is a global, comprehensive, Life Sciences database encompassing the Biotechnology, Pharmaceutical and Medical Device industries. www.biotechgate.com

The Nodric Life Sciences Database is a part of the global Biotechgate. Our Swedish partners include SwedenBIO, Invest in Skåne, Medicon Valley, Stockholm-Uppsala Life Science and Business Region Göteborg. www.nordic-lifesciences.com

Biotechgate is owned and operated by Venture Valuation AG, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the Life Sciences (Biotech, Pharma, Medtech), ICT, high-tech, Nanotech, Cleantech and Renewable energy. www.venturevaluation.com

Overview of the Swedish Life Science Industry

2015 Statistics

Total Biotech Companies 416

Medtech companies 303

Pharma companies 41

Investor companies 26

Public / Non-Profit Organizations / Medical Facilities 121

Other life science related companies 887

Percentage of Publicly Owned Companies 8.8%

Life Sciences Venture Financing 2013 / 2014 USD 46.3m / USD 81.6m

Number of Technologies 114

Licensing Opportunities 87

Overview of the Swedish Biotechnology Industry

2015 Statistics

Total Biotech Companies 416

Biotech - Therapeutics 120

Biotech – R&D Services 187

Biotech - Other 109

Percentage of SME's 94.3%

Percentage of Publicly Owned Companies 8.9%

Biotech Venture financing 2013 / 2014 USD 25.9m / USD 80.8m

Licensing Opportunities 77

Number of Employees

Number of Employees - Life Sciences

1-1037%

11-5030%

51-20022%

Greater than 200

12%

Number of Employees - Life Sciences

1-1045%

11-5034%

51-20015%

Greater than 200

6%

Number of Employees - Biotech

Company Ownership

Life Science Companies by Ownership Status

Life Science companies include Biotech, Medtech and Pharmaceutical companies.

Private / inde-

pendent67.0%

Public8.8%

Sub-sidiary24.2%

Life Science Companies by Ownership Status

Private / independent 74.0 %Public

8.9%

Subsidiary19.0%

Biotechnology Companies by Ownership Status

Company Foundation Timeline

20052006

20072008

20092010

20112012

20132014

0

2

4

6

8

10

12

14

16

18

20

Number of Biotech Companies Founded by Year

Biotechnology - other Biotechnology - Therapeutics and Diagnostics Biotechnology / R&D Services

Key Activities of Biotechnology Companies

AgroBio3% Bioinformatics and Bioelectronics

3%

Contract Research and Manufacturing13%

Cosmetics2%

Diagnostics and Analytical Services16%

Drug Delivery3%

Environment2%

Food and Nutraceuticals8%

Genomics and Proteomics5%

Industrial Biotechnology2%

Other Services and Suppliers22%

Therapeutics18%

Veterinary4%

Key Biotech Activity

Biotech Products - Breakdown by Indication

Biotech Products by Indication

Neoplasms / cancer / oncologyDiseases of the nervous systemInfectious and parasitic diseases

otherEndocrine, nutritional and metabolic diseases

CardiovascularDiseases of the blood and blood-forming organs; immune disorders

Musculoskeletal system and connective tissueGenitourinary system

Digestive systemSkin and subcutaneous tissue

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classifiedRespiratory

Mental and behavioural disordersInjury, poisoning and certain other consequences of external causes

Diseases of the eyePregnancy, childbirth and the puerperiumExternal causes of morbidity and mortality

Diseases of the ear

0 10 20 30 40 50 60 70 80

Biotech Products by Indication

Products in the Pipeline as of 07.10.2015

Phase III

Phase II

Phase I

Preclinical

0 10 20 30 40 50 60 70 80

25

69

28

72

Number of Biotech Products in Development

Biotechnology Financing in Sweden – 5 year report

2010 H1 Pri-

vate

2010 H2 Pri-

vate

2011 H1 Pri-

vate

2012 H1 Pri-

vate

2012 H2 Pri-

vate

2013 H1 Pri-

vate

2013 H2 Pri-

vate

2014 H1 Pri-

vate

2014 H2 Pri-

vate

2015 H1 Pri-

vate

2015 H2 Pri-

vate

2010 H1 Pri-

vate

2010 H2 Pri-

vate

2011 H1 Pri-

vate

2012 H1 Pri-

vate

2012 H2 Pri-

vate

2013 H1 Pri-

vate

2013 H2 Pri-

vate

2014 H1 Pri-

vate

2014 H2 Pri-

vate

2015 H1 Pri-

vate

2015 H2 Pri-

vate

Fi-nanc-ing Value

0 1.27985907781726

23.9762624532287

8.29371865204861

5.13974509509335

10.8783662885837

14.9717981912417

73.9208130627984

6.8740006078734

3.45407648312212

0.93996005169780

3

Number of Rounds

0 3 4 3 5 3 1 7 5 2 1

5.015.025.035.045.055.065.075.0

0.51.52.53.54.55.56.57.5

Venture Financing of Biotech CompaniesFinancing ValueNumber of Rounds

Fina

ncin

g Va

lue

(Mill

ion

USD)

Num

ber o

f Rou

nds

Major Biotech Financing Rounds (2015)

Company Sector USD M

Pharmalink AB Biotech – Therapeutics & Diagnostics 15.0

OxThera AB Biotech – Therapeutics & Diagnostics 10.7

Glionova Therapeutics Biotech – Therapeutics & Diagnostics 5.7

About Biotechgate

Biotechgate contains over 35’000 high quality company profiles which include company descriptions, contact information, product pipeline information, financing rounds and management details. Profiles are regularly updated by the companies themselves, as well as by an experienced database team, to ensure the accuracy and relevance of the data.

To register for a trial or to learn more about the different subscription options, please visit www.biotechgate.com

Terms of Use

The “Swedish Life Sciences Trend Analysis” is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.

Biotechgatec/o Venture Valuation VV AGKasernenstrasse 118004 ZurichSwitzerland

+41 (43) 321 86 60 www.venturevaluation.com